Scholar Rock Holding (SRRK) Valuation Check After Strong Recent Share Price Momentum
AI Sentiment
Positive
6/10
as of 02-06-2026 4:00pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.6B | IPO Year: | 2018 |
| Target Price: | $51.20 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.71 - $49.82 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 20029.43% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -274644000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$46.36
Shares
14,898
Total Value
$695,937.54
Owned After
85,660
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$44.48
Shares
8,406
Total Value
$373,879.55
Owned After
85,660
SEC Form 4
CHRO
Avg Cost/Share
$44.48
Shares
6,600
Total Value
$293,552.82
Owned After
148,864
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$44.48
Shares
5,798
Total Value
$257,881.70
Owned After
95,687
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$45.20
Shares
13,112
Total Value
$592,611.26
Owned After
85,660
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$42.70
Shares
16,746
Total Value
$715,054.20
Owned After
583,254
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$42.70
Shares
16,755
Total Value
$715,438.50
Owned After
583,245
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$42.70
Shares
57,450
Total Value
$2,453,115.00
Owned After
1,541,645
SEC Form 4
President of R&D
Avg Cost/Share
$42.70
Shares
20,438
Total Value
$872,702.60
Owned After
595,767
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sell | $46.36 | 14,898 | $695,937.54 | 85,660 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 16, 2026 | Sell | $44.48 | 8,406 | $373,879.55 | 85,660 | |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16, 2026 | Sell | $44.48 | 6,600 | $293,552.82 | 148,864 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jan 16, 2026 | Sell | $44.48 | 8,016 | $356,533.24 | 214,553 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Jan 16, 2026 | Sell | $44.48 | 5,798 | $257,881.70 | 95,687 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Sell | $45.20 | 13,112 | $592,611.26 | 85,660 | |
| Woods Keith | SRRK | Chief Operating Officer | Jan 13, 2026 | Sell | $42.70 | 16,746 | $715,054.20 | 583,254 | |
| Sinha Vikas | SRRK | Chief Financial Officer | Jan 13, 2026 | Sell | $42.70 | 16,755 | $715,438.50 | 583,245 | |
| Hallal David | SRRK | Chief Executive Officer | Jan 13, 2026 | Sell | $42.70 | 57,450 | $2,453,115.00 | 1,541,645 | |
| Vaishnaw Akshay | SRRK | President of R&D | Jan 13, 2026 | Sell | $42.70 | 20,438 | $872,702.60 | 595,767 |
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
6/10
See how SRRK stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.